Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
Open-label, prospective study investigated the effects of preemptive administration of tocilizumab in pediatric patients with B-ALL undergoing CAR-T therapy.
Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.